VF, F., AG, P., DK, K., NM, M., & VG, G. (2012). Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: A cost minimization analysis. Dove Medical Press.
Style de citation Chicago (17e éd.)VF, Fragoulakis, Pallis AG, Kaitelidou DK, Maniadakis NM, et Georgoulias VG. Economic Evaluation of Pemetrexed Versus Erlotinib as Second-line Treatment of Patients with Advanced/metastatic Non-small Cell Lung Cancer in Greece: A Cost Minimization Analysis. Dove Medical Press, 2012.
Style de citation MLA (8e éd.)VF, Fragoulakis, et al. Economic Evaluation of Pemetrexed Versus Erlotinib as Second-line Treatment of Patients with Advanced/metastatic Non-small Cell Lung Cancer in Greece: A Cost Minimization Analysis. Dove Medical Press, 2012.